Highlights and Quick Summary
Current Net Cash/Marketcap of AbbVie Inc. is $0.212 (as of December 30, 2019)
- Net Cash/Marketcap for the quarter ending December 30, 2019 was $0.212 (a -14.46% decrease compared to previous quarter)
- Year-over-year quarterly Net Cash/Marketcap decreased by -20.71%
- Annual Net Cash/Marketcap for 2019 was $0.212 (a -6.74% decrease from previous year)
- Annual Net Cash/Marketcap for 2018 was $0.227 (a 29.27% increase from previous year)
- Annual Net Cash/Marketcap for 2017 was $0.176 (a -41.56% decrease from previous year)
Visit stockrow.com/ABBV
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Net Cash/Marketcap of AbbVie Inc.
Most recent Net Cash/Marketcapof ABBV including historical data for past 10 years.Interactive Chart of Net Cash/Marketcap of AbbVie Inc.
AbbVie Inc. Net Cash/Marketcap for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2019 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 |
| 2018 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 |
| 2017 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 |
| 2016 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 |
| 2015 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 |
| 2014 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 |
| 2013 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 |
| 2012 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 |
| 2011 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 |
| 2010 | – | – | – | – | $0.0 |
| 2009 | – | – | – | – | $0.0 |
Business Profile of AbbVie Inc.
Sector: Medical
Industry: Drugs
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. It offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, it offers AndroGel, a testosterone replacement therapy; CREON, a pancreatic enzyme therapy; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide molecule gonadotropin-releasing hormone antagonist. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; Calico Life Sciences LLC; Cystic Fibrosis Foundation; Dragonfly Therapeutics, Inc.; and Pan-Canadian Pharmaceutical Alliance. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.